98%
921
2 minutes
20
Scientific publications are the building blocks of discovery and collaboration, but their impact is limited by the style in which they are traditionally written. Recently, many authors have called for a switch to an engaging, accessible writing style. Here, we experimentally test how readers respond to such a style. We hypothesized that scientific abstracts written in a more accessible style would improve readers' reported readability and confidence as well as their understanding, assessed using multiple-choice questions on the content. We created a series of scientific abstracts, corresponding to real publications on three scientific topics at four levels of difficulty-varying from the difficult, traditional style to an engaging, accessible style. We gave these abstracts to a team of readers consisting of 170 third-year undergraduate students. Then, we posed questions to measure the readers' readability, confidence, and understanding with the content. The scientific abstracts written in a more accessible style resulted in higher readability, understanding, and confidence. These findings demonstrate that rethinking the way we communicate our science may empower a more collaborative and diverse industry.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430246 | PMC |
http://dx.doi.org/10.3389/fpsyg.2021.714321 | DOI Listing |
Ann Surg Oncol
September 2025
Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health and Science University School of Medicine, Portland, OR, USA.
Encephale
September 2025
Département de psychiatrie de l'adolescent et du jeune adulte, institut mutualiste Montsouris, 42, boulevard Jourdan, Paris, France; UVSQ, Inserm U1178, PsyDev, CESP université Paris-Saclay, Villejuif, France; Université Paris-Cité, Paris, France.
The body of knowledge on trauma is rapidly expanding. Since 2022, the WHO has been calling for the history of adversity to be systematically taken into account when assessing the state of health of all individuals. But at this stage, our understanding of the precise mechanisms of complex trauma remains incomplete.
View Article and Find Full Text PDFZhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, G
Biologics play a critical role in the treatment of severe bronchial asthma. Both () and in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab.
View Article and Find Full Text PDFZhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of nursing, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are important treatments for EGFR mutant non-small cell lung cancer (NSCLC). However, the first and second generation EGFR-TKI face clinical limitations due to acquired resistance, such as the T790M mutation. Irreversible EGFR-TKI can significantly prolong the survival of patients by enhancing the inhibition of drug-resistant mutations through the covalent binding mechanism.
View Article and Find Full Text PDFZhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Immune-related adverse events (irAE) are treatment-associated complications that single or multiple systems could be involved after immune checkpoint inhibitors(ICI), ranging from mild to life-threatening diseases, with significant heterogeneity. This is an important factor which might affect continuous ICI treatment. Patients who have experienced mild to moderate irAE could try ICI rechallenge after they recovered from irAE.
View Article and Find Full Text PDF